Navigation Links
Gardasil Demonstrates Up to 100% Efficacy

dies, including more than 17,000 womenb),c), Gardasil® provided benefits against pre-cancerous (CIN2/3) and potentially pre-cancerous cervical lesions (CIN1) caused by additional virus types not directly targeted by the vaccine. The additional virus types cause more than 10% of cervical cancer and substantial proportions of pre-cancerous and potentially pre-cancerous cervical lesions. The data have recently been submitted to the European Medicines Agency (EMEA) and the US Food and Drug Administration in order to update the marketing authorisation for Gardasil®.

The burden of cervical cancer and other Human Papillomavirus diseases
Despite screening for early detection, cervical cancer remains the second most common cause of death from cancer (after breast cancer) among young women (15-44 years) in Europe . Around 33,500 women are diagnosed with, and 15,000 women die from cervical cancer each year (the equivalent of 40 women per day or nearly 2 per hour).
In addition, hundreds of thousands of women are diagnosed with other Human Papillomavirus diseases that start before cervical cancer and go beyond the cervix. These diseases include pre-cancerous and potentially pre-cancerous cervical lesions7,9, , vulvar and vaginal cancer5,6, , pre-cancerous vulvar and vaginal lesions10,11, , and genital warts.
Cervical cancer is caused by Human Papillomavirus. , The virus is very common, with 70% of sexually active people estimated to become exposed at some point in life. , , Genital infections with Human Papillomavirus are very common with the majority of infections occurring in adolescence or early adulthood. ,

EU indication of Gardasil®
According to the licence in the EU, Gardasil®, Human Papillomavirus Vaccine [types 6,11,16,18] (Recombinant, adsorbed), can be given to children and adolescents 9 to15 years and adult females 16 to 26 years of age and is indicated for the prevention of cervical carcinoma (cervic
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Data Published in The Lancet Show Gardasil was 100 Percent Effective in Preventing High-Grade Vulvar and Vaginal Lesions Caused by HPV Types 16 and 18
2. New England Journal of Medicine Publishes New Data on Gardasil, Mercks Cervical Cancer Vaccine
3. The International Myeloma Foundation Says Data Reported at a Global Medical Meeting in Greece Demonstrates Improved Survival for a Wide Range of Myeloma Patients
4. Publication on Pixantrone Preclinical Studies Demonstrates Reduced Cardiotoxicity Compared to Equiactive Doses of Doxorubicin and Mitoxantrone
5. New Research Demonstrates Broad Efficacy of Azixa (MPC-6827) Against Multiple Tumor Types and in Drug Resistant Cell Lines
6. Algeta Demonstrates Targeted Cancer-killing Potential of Novel Alpha Particle Linked Antibodies in Leading Medical Journal Blood
7. Gerons Telomerase Inhibitor Cancer Drug Demonstrates Good Pharmacokinetics and Tolerability in Phase I/II Trial
8. Frova Phase III Study Data Demonstrates That Short-Term Prevention Treatment Reduces Frequency and Severity of Menstrual Migraine
9. Mymetics HIV Vaccine Demonstrates First-Ever Production of Neutralizing IgA Antibodies in Non-Human Primate Model
10. Newly Published Data Demonstrates Superiority of Cipralex Over Duloxetine for Acute Treatment of Depression
11. Introgens Advexin Demonstrates Clinical Benefit in Inherited Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Gardasil Demonstrates Efficacy
(Date:7/11/2014)... July 11, 2014 Research and Markets ... the "Immunoprotein Diagnostic Testing Market - Forecasts ... CAGR of 6% and is expected to be ... their offering. http://photos.prnewswire.com/prnh/20130307/600769 ... testing has been segmented according to immunoprotein types ...
(Date:7/11/2014)... , July 11, 2014 ... visitors to Safety & Health Expo 2014 ... the move to London ... management attending exhibition.     ... http://photos.prnewswire.com/prnh/20140711/696892-a )      ...
(Date:7/10/2014)... India , July 11, 2014  Major ... treatment of cancer are being highlighted in a ... Mumbai from 10-12 July, 2014.  Renowned national ... to share best practices and exchange knowledge on ... precise, accurate and efficient. The ...
Breaking Medicine Technology:Immunoprotein Diagnostic Testing Market - Forecasts to 2019: Expected to grow at the highest CAGR of 6% and is expected to be valued at USD 4,943.0 million 2UK's Flagship Health & Safety Event Has Successful Inaugural Year in London 2UK's Flagship Health & Safety Event Has Successful Inaugural Year in London 3UK's Flagship Health & Safety Event Has Successful Inaugural Year in London 4Improving quality and access to advanced cancer care in India and South Asia 2Improving quality and access to advanced cancer care in India and South Asia 3Improving quality and access to advanced cancer care in India and South Asia 4Improving quality and access to advanced cancer care in India and South Asia 5
... , SOUTH SAN FRANCISCO, Calif., July 8 Rigel Pharmaceuticals, ... Company plans to host a conference call on Thursday, July ... Members of Rigel,s senior management team and the principal investigator ... 2b TASKi2 clinical trial of R788 in rheumatoid arthritis, the ...
... OAKS, Calif., July 7 Amgen (Nasdaq: ... head-to-head trial evaluating denosumab versus Zometa(R) (zoledronic acid) in ... advanced breast cancer met its primary and secondary endpoints ... was demonstrated for both delaying the time to the ...
Cached Medicine Technology:Rigel to Host Conference Call to Discuss Results of Its Phase 2b TASKi2 Clinical Trial of R788 in Rheumatoid Arthritis 2Denosumab Demonstrates Superiority Over Zometa(R) in Pivotal Phase 3 Head-to-Head Trial in Breast Cancer Patients With Bone Metastases 2Denosumab Demonstrates Superiority Over Zometa(R) in Pivotal Phase 3 Head-to-Head Trial in Breast Cancer Patients With Bone Metastases 3Denosumab Demonstrates Superiority Over Zometa(R) in Pivotal Phase 3 Head-to-Head Trial in Breast Cancer Patients With Bone Metastases 4Denosumab Demonstrates Superiority Over Zometa(R) in Pivotal Phase 3 Head-to-Head Trial in Breast Cancer Patients With Bone Metastases 5Denosumab Demonstrates Superiority Over Zometa(R) in Pivotal Phase 3 Head-to-Head Trial in Breast Cancer Patients With Bone Metastases 6Denosumab Demonstrates Superiority Over Zometa(R) in Pivotal Phase 3 Head-to-Head Trial in Breast Cancer Patients With Bone Metastases 7Denosumab Demonstrates Superiority Over Zometa(R) in Pivotal Phase 3 Head-to-Head Trial in Breast Cancer Patients With Bone Metastases 8
(Date:7/12/2014)... Wright & Schulte LLC has filed a DePuy Pinnacle ... Johnson & Johnson, on behalf of an Ohio man who ... DePuy Pinnacle hip replacement and had to undergo revision surgery ... DePuy hip lawsuit was filed July 7, 2014, in the ... where DePuy Pinnacle Hip lawsuit litigation is underway . ...
(Date:7/12/2014)... New York, NY (PRWEB) July 12, 2014 ... (the National Institute of Standards and Technology), the June ... up the electronic discovery world. It was ... was finally in, depending on whether it was seen from ... But this much is fact, there is now precedent ...
(Date:7/12/2014)... article released by Seattle's well known plastic surgeon, Dr. Bryan ... cosmetic surgical procedures in summer months . , As ... enliven the rainy Pacific Northwest, many people are turning their ... out as much during the winter as they had planned. ... eager to look their best for their summer vacations, and ...
(Date:7/12/2014)... Restore My Vision Today is a ... a couple boasting very impressive credentials on the field ... Today as a way to help consumers do without ... their respective patients’ treatments . , In ... trove of pertinent information relevant to eye care like:, ...
(Date:7/12/2014)... The largest pure occupational medicine company in the ... it will be opening its fifth Georgia center in ... Atlanta-based Nova Medical Centers’ locations. The Augusta facility ... and will be open from 8:30 a.m. to 6 ... philosophy of rapid return-to-work and decreased treatment times for ...
Breaking Medicine News(10 mins):Health News:DePuy Pinnacle Hip Lawsuit Filed By Wright & Schulte LLC On Behalf of Ohio Man Who Required Revision Surgery Purportedly From Defective Hip Implant 2Health News:DePuy Pinnacle Hip Lawsuit Filed By Wright & Schulte LLC On Behalf of Ohio Man Who Required Revision Surgery Purportedly From Defective Hip Implant 3Health News:DePuy Pinnacle Hip Lawsuit Filed By Wright & Schulte LLC On Behalf of Ohio Man Who Required Revision Surgery Purportedly From Defective Hip Implant 4Health News:DePuy Pinnacle Hip Lawsuit Filed By Wright & Schulte LLC On Behalf of Ohio Man Who Required Revision Surgery Purportedly From Defective Hip Implant 5Health News:Mobile Device Forensics Guidelines Play Key Role in Supreme Court’s Smartphone Evidence Warrant Decision 2Health News:Mobile Device Forensics Guidelines Play Key Role in Supreme Court’s Smartphone Evidence Warrant Decision 3Health News:Mobile Device Forensics Guidelines Play Key Role in Supreme Court’s Smartphone Evidence Warrant Decision 4Health News:Mobile Device Forensics Guidelines Play Key Role in Supreme Court’s Smartphone Evidence Warrant Decision 5Health News:Best Summer Cosmetic Surgeries Revealed in Article By Seattle Plastic Surgeon 2Health News:Restore My Vision Today | Groundbreaking Book Reveals How To Restore Your Vision Without The Use of Glasses – Vinamy 2Health News:Restore My Vision Today | Groundbreaking Book Reveals How To Restore Your Vision Without The Use of Glasses – Vinamy 3Health News:Nova Medical Centers To Open New Facility in Augusta, Georgia 2
... Students to Get Fit By Finals, , Awards School with ... Chicago Bulls legend BJ Armstrong is rallying Chicago ... new national campaign called Get Fit By Finals . ... "got milk?" Body By Milk(R) Campaign and NBA FIT, the NBA,s ...
... galectin-3 may serve as treatment target against disease ... -- A newly identified marker for prostate cancer ... treatment, University of Michigan researchers say. , Previous ... marker galectin-3 are linked with neoplastic progression in ...
... Will Earn Decision Resources, Clinical Gold Standard Status ... a New Report from Decision ResourcesWALTHAM, Mass., March ... leading research and advisory firms for pharmaceutical and ... a therapy,s effect on the rate of mortality ...
... 2008 Frost & Sullivan European Human Growth ... to Ferring Pharmaceuticals. The award is in ... injection for human growth hormone (hGH). The ... VISION X, innovative no-needle delivery systems for ...
... WELLINGTON, Fla., March 25 The Quantum Group, Inc. ... announced it has implemented a reallocation of ... the PWeR(TM) (pronounced POWER) platform. As Quantum continues ... the Company expects for the PWeR platform, it has ...
... Osteoarthritis Sufferers to Live Fit by Thinking Fit, Eating ... 25 Today, Bob Greene, best-selling author and personal ... the 27 million Americans who suffer from osteoarthritis (OA) ... Pharmaceuticals (Nasdaq: ENDP ), the MOVE (Managing ...
Cached Medicine News:Health News:Got Milk?(R) and the NBA Showcase New National Teen Health and Fitness Initiative at Cesar E. Chavez Multicultural Center 2Health News:Got Milk?(R) and the NBA Showcase New National Teen Health and Fitness Initiative at Cesar E. Chavez Multicultural Center 3Health News:Got Milk?(R) and the NBA Showcase New National Teen Health and Fitness Initiative at Cesar E. Chavez Multicultural Center 4Health News:Got Milk?(R) and the NBA Showcase New National Teen Health and Fitness Initiative at Cesar E. Chavez Multicultural Center 5Health News:Surveyed Experts Indicate that Biogen Idec's Adentri Has Advantages Over Nitroglycerin in the Treatment of Acute Heart Failure 2Health News:Surveyed Experts Indicate that Biogen Idec's Adentri Has Advantages Over Nitroglycerin in the Treatment of Acute Heart Failure 3Health News:Frost & Sullivan Accolade for Ferring Pharmaceuticals 2Health News:Frost & Sullivan Accolade for Ferring Pharmaceuticals 3Health News:The Quantum Group Announces Resource Reallocation to Advance PWeR(TM) Platform 2Health News:The Quantum Group Announces Resource Reallocation to Advance PWeR(TM) Platform 3Health News:The Quantum Group Announces Resource Reallocation to Advance PWeR(TM) Platform 4Health News:The Quantum Group Announces Resource Reallocation to Advance PWeR(TM) Platform 5Health News:Exercise Physiologist and Celebrity Trainer Bob Greene Leads National Campaign to Showcase Osteoarthritis Pain Management Techniques and New Treatment Approaches 2Health News:Exercise Physiologist and Celebrity Trainer Bob Greene Leads National Campaign to Showcase Osteoarthritis Pain Management Techniques and New Treatment Approaches 3Health News:Exercise Physiologist and Celebrity Trainer Bob Greene Leads National Campaign to Showcase Osteoarthritis Pain Management Techniques and New Treatment Approaches 4Health News:Exercise Physiologist and Celebrity Trainer Bob Greene Leads National Campaign to Showcase Osteoarthritis Pain Management Techniques and New Treatment Approaches 5Health News:Exercise Physiologist and Celebrity Trainer Bob Greene Leads National Campaign to Showcase Osteoarthritis Pain Management Techniques and New Treatment Approaches 6Health News:Exercise Physiologist and Celebrity Trainer Bob Greene Leads National Campaign to Showcase Osteoarthritis Pain Management Techniques and New Treatment Approaches 7